This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Should iShares Russell MidCap Growth ETF (IWP) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IWP
IDEXX (IDXX) Q1 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
Strong sales at the CAG and Water businesses drove IDEXX's (IDXX) first-quarter 2022 revenues.
Idexx Laboratories (IDXX) Q1 Earnings Beat Estimates
by Zacks Equity Research
Idexx (IDXX) delivered earnings and revenue surprises of 0.89% and 0.57%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
MedTech Stocks' Q1 Earnings Due on May 4: CRL, IDXX & NUVA
by Urmimala Biswas
MedTech companies' results are likely to reflect a rebound in the base business. Let's see how CRL, IDXX and NUVA fare this time.
Earnings Preview: Idexx Laboratories (IDXX) Q1 Earnings Expected to Decline
by Zacks Equity Research
Idexx (IDXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IDEXX (IDXX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Strength in CAG Diagnostics and Water businesses is likely to have contributed to IDEXX's (IDXX) top line in the first quarter.
Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?
by Zacks Equity Research
Sector ETF report for PTH
IDEXX (IDXX) CAG Sales Gain Traction, FX Headwind Persists
by Zacks Equity Research
IDEXX (IDXX) has been witnessing continued high CAG Diagnostics recurring revenue growth across major regions with solid gains across its key in-clinic platforms.
Accuray's (ARAY) CyberKnife Effective for Relief From TN Pain
by Zacks Equity Research
Latest data indicates that Accuray's (ARAY) CyberKnife System is effective in providing long-lasting pain relief to patients suffering from TN.
3 Reasons to Retain Accuray (ARAY) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Accuray (ARAY) owing to its solid global reach.
Masimo (MASI) Reports Preliminary Q1 Results, Reiterates '22 View
by Zacks Equity Research
Masimo's (MASI) first-quarter 2022 results are likely to have been dampened by supply chain headwinds.
LHC Group's (LHCG) Deal With Optum to Boost Value-Based Care
by Zacks Equity Research
LHC Group's (LHCG) deal with Optum is likely to enhance and extend value-based care to patients' homes.
Here's Why You Should Retain Nevro (NVRO) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Nevro (NVRO) owing to its strength in the global SCS market.
Veeva Systems (VEEV) Sees Wider Adoption of Its Development Cloud
by Zacks Equity Research
Adoption of Veeva Systems' (VEEV) cloud applications is likely to significantly boost its Veeva Development Cloud business.
Reasons to Retain Ecolab (ECL) Stock in Your Portfolio For Now
by Zacks Equity Research
Investors continue to be optimistic about Ecolab (ECL) owing to its solid product portfolio.
Henry Schein (HSIC) Digital Dentistry Gains, Expands Globally
by Zacks Equity Research
Henry Schein (HSIC) witnesses strength in dental consumable merchandise sales in France, Germany, Austria, Belgium.
Here's Why You Should Invest in IDEXX (IDXX) Stock for Now
by Zacks Equity Research
Investors are optimistic about IDEXX's (IDXX) strong international performances and favorable 2022 outlook.
Here's Why You Should Retain Globus Medical (GMED) Stock Now
by Zacks Equity Research
Investors are optimistic about Globus Medical's (GMED) better-than-expected results and strength in the U.S. Spine business.
Phibro (PAHC) Rises 6.1% Since Q2 Earnings: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Phibro's (PAHC) booming vaccine business and strong global presence.
National Vision (EYE) Hurt by Rising Costs, Vendor Dependency
by Zacks Equity Research
High dependence on a limited number of suppliers exposes National Vision (EYE) to supplier concentration risk.
Quest Diagnostics' (DGX) Volumes Aid, Price Pressure Stays
by Zacks Equity Research
According to Quest Diagnostics (DGX), the delay of the 2022 PAMA cuts announced last year proved beneficial for the industry and Medicare beneficiaries.
Quest Diagnostics' (DGX) New Contract to Aid COVID-19 Research
by Zacks Equity Research
Quest Diagnostics' (DGX) COVID-19 serological tests, nationwide reach and data analytics capabilities will help assess COVID-19 vulnerability throughout the country.
Should iShares Russell MidCap Growth ETF (IWP) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IWP
Integra (IART) Debuts NeuraGen 3D for Peripheral Nerve Repair
by Zacks Equity Research
Integra's (IART) NeuraGen 3D will provide surgeons with access to the latest technology in peripheral nerve repair.
Reasons to Add Surmodics (SRDX) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Surmodics (SRDX) owing to its consistent efforts to boost R&D.